SCHEMBL4401026

SCHEMBL4401026

O=C(CF)Oc1ccccc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.61
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
RECQL P46063 1/20 0.61
HSD17B10 Q99714 7/20 0.61
HPGD P15428 5/20 0.61
ALDH1A1 P00352 8/20 0.59
ESR1 P03372 1/20 0.59
ITGB3 P05106 1/20 0.59
ITGA2B P08514 1/20 0.59
HMGB1 P09429 1/20 0.59
TSHR P16473 1/20 0.59
GGT1 P19440 1/20 0.59
PTGS1 P23219 1/20 0.59
PTGS2 P35354 1/20 0.59
BLM P54132 1/20 0.59
NAPRT Q6XQN6 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
MAPT P10636 2/20 0.58
LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL844727 0.85 KDM4E (0.70) KDM4EKMT2AMEN1RECQLHSD17B10
Diaspirin SCHEMBL40799 0.85 KDM4E (0.75) KDM4EKMT2AMEN1RECQLHSD17B10
Diaspirin SCHEMBL30735506 0.85 KDM4E (0.75) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL8436639 0.83 KDM4E (0.63) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL25946877 0.82 KDM4E (0.67) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL2763226 0.81 KDM4E (0.71) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL6129343 0.81 KDM4E (0.61) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL13006825 0.81 KDM4E (0.72) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL3765406 0.81 KDM4E (0.81) KDM4EKMT2AMEN1RECQLHSD17B10
SCHEMBL7529982 0.81 KDM4E (0.61) KDM4EKMT2AMEN1RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572907-B2 Methods and compounds for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2009-08-11 US disclosed
EP-1717242-A1 Polynucleotide synthesis Agilent Technologies, Inc. (US) 2006-11-02 EP disclosed
US-20060247430-A1 Methods and compounds for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. 2006-11-02 US disclosed
EP-0950669-B1 Method of catalytic crosslinking of polymers and two-pack composition used therein ROHM & HAAS (US) 2004-09-08 EP disclosed
US-6306991-B1 TWO PART COATING COMPOSITION WITH TWO CONTAINERS, OXIDATIVE POLYMERS WITH CROSSLINKABLE FUNCTIONAL GROUPS ROHM AND HAAS COMPANY 2001-10-23 US disclosed
US-6149977-A CONTACTING THE OXIDATIVE POLYMER WITH A CATALYTIC AMOUNT OF AN OXIDIZING ENZYME, SUCH AS HORSERADISH PEROXIDASE. ROHM AND HAAS COMPANY (US) 2000-11-21 US disclosed
EP-0950669-A2 Method of catalytic crosslinking of polymers and two-pack composition used therein ROHM AND HAAS COMPANY (US) 1999-10-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247430-A1 Methods and compounds for polynucleotide synthesis POLN, POLRMT, POLM KDM4E 4662/4885KMT2A 3846/4885MEN1 3222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.